Latest news with #Dublin-headquartered
Economic Times
a day ago
- Business
- Economic Times
Advent International to acquire stake in Felix Pharmaceuticals
Advent International, a leading global private equity investor, signed a definitive agreement to invest $175 million via primary and secondary for a significant minority stake in Dublin-headquartered Felix Pharmaceuticals, a leading global generic animal pharma player, stated a company release. Felix Pharma is a manufacturer of off-patent medicines for companion animals. Felix develops, manufactures and supplies to distributors and other branded generic players for private labelling, particularly in the US. With a portfolio of 14 approved products from USFDA and many more under review and development, Felix has the widest portfolio of products in the industry. 'Felix is well positioned to lead this generic space with its strong leadership, broad portfolio, and robust R&D and commercial capabilities. Its rapid growth and high customer satisfaction make it a differentiated platform, and we are excited to support Neeraj and the Felix team in scaling it into a global franchise,' said Shweta Jalan, Managing Partner at Advent. Felix was founded in 2015 by Neeraj Agrawal, Sir Jonathan Symonds and Dr Shumeet Banerji, ex-CEO of Booz-Allen. While the company achieved its first US FDA approval in 2020, marking a pivotal step in its expansion, it has quickly scaled to a 14 commercialised product portfolio and has several others in advanced stages of pipeline, it said. It has a USFDA approved oral solid facility dedicated for animal health products and an injectable facility that is expected to be ready by Q3 2025. Neeraj Agrawal, Co-Founder of Felix Pharma, said, 'As we scale in a fast-evolving market, we were looking for a partner who brings not just capital, but also deep operating expertise and the right mindset and networks to help us grow faster and stronger.'
Time of India
a day ago
- Business
- Time of India
Advent International to acquire stake in Felix Pharmaceuticals
Advent International , a leading global private equity investor , signed a definitive agreement to invest $175 million via primary and secondary for a significant minority stake in Dublin-headquartered Felix Pharmaceuticals , a leading global generic animal pharma player, stated a company release. Felix Pharma is a manufacturer of off-patent medicines for companion animals. Felix develops, manufactures and supplies to distributors and other branded generic players for private labelling, particularly in the US. With a portfolio of 14 approved products from USFDA and many more under review and development, Felix has the widest portfolio of products in the industry. 'Felix is well positioned to lead this generic space with its strong leadership, broad portfolio, and robust R&D and commercial capabilities. Its rapid growth and high customer satisfaction make it a differentiated platform, and we are excited to support Neeraj and the Felix team in scaling it into a global franchise,' said Shweta Jalan, Managing Partner at Advent. Felix was founded in 2015 by Neeraj Agrawal, Sir Jonathan Symonds and Dr Shumeet Banerji, ex-CEO of Booz-Allen. While the company achieved its first US FDA approval in 2020, marking a pivotal step in its expansion, it has quickly scaled to a 14 commercialised product portfolio and has several others in advanced stages of pipeline, it said. It has a USFDA approved oral solid facility dedicated for animal health products and an injectable facility that is expected to be ready by Q3 2025. Neeraj Agrawal, Co-Founder of Felix Pharma, said, 'As we scale in a fast-evolving market, we were looking for a partner who brings not just capital, but also deep operating expertise and the right mindset and networks to help us grow faster and stronger.'
Irish Independent
3 days ago
- Business
- Irish Independent
US judge dismisses Ireland-based multinational's GDPR fears in ruling on handover of Irish-based staff files
American power giant Eaton had asked court to reconsider order to surrender performance data to US taxman, citing data privacy fears Today at 21:30 A Dublin-headquartered multinational has been told to ignore GDPR rules in a long-running US legal case over access to Irish employee related data. The American judge argued any resulting fine from the Irish Data Protection Commissioners here would likely only be 'marginal', a view that is likely to be highly controversial with European regulators and privacy campaigners.
Irish Examiner
28-05-2025
- Business
- Irish Examiner
Bulmers owner C&C Group reports minimal impact from tariffs
Bulmers owner, the C&C Group, delivered revenues of €1.7bn for the 12 months to the end of February with the Dublin-headquartered firm reporting a limited impact from tariffs. Reporting its financial results, the company said its flagship products, Bulmers and Tennent's, achieved market share gains, maintaining market-leading positions. C&C Group is proposing a final dividend of 4.13c per share up from 3.96c for the 2024 financial year. The company's share price is up 5.7% year to date. Net revenues of €1,665m is up €13m on the previous year. Roger White, Group Chief Executive Officer, said: "The Group has progressed on a number of fronts over the last year, despite the ongoing challenging macro and market backdrop." "Our two leading brands, Tennent's and Bulmers gained market share and we see future growth opportunities for both. Our Premium brand performance is encouraging, benefitting from ongoing consumer appeal for premium beer and cider which is driving growth in this segment." 'Looking ahead, year-to-date trading is encouraging. With the key summer trading period ahead, we are executing our plans for the year, supporting our customers, investing in innovation and brand-building, people, and systems, whilst continuing to simplify the business and control costs."
RTÉ News
22-05-2025
- Business
- RTÉ News
Staff at Storyful share bonus payments of €1.07m over two years as losses narrow
Staff at the Rupert Murdoch-owned Dublin-headquartered social media intelligence and online news agency, Storyful have shared bonus payments of €1.07m over the past two years. New accounts show that staff at Storyful Ltd shared a "staff bonus" of €556,958 in the 12 months to the end of June last and this followed a bonus payout of €515,135 in 2023. The News Corporation-owned Storyful Ltd accounts show that pre-tax losses at the business last year narrowed by 14% from €3.08m to €2.66m. The business reduced its losses as revenues decreased by 18% from €4.19m to €3.44min the 12 months to the end of June last. The Irish unit recorded the losses as the company "continued to expand services for media, brands and social platforms and made investments in the product and technology departments". The directors stress that not all of Storyful's global revenue figures are included in these results "and therefore this report should be interpreted only with respect to Storyful Ltd". The firm's administrative expenses reduced from €5.23m to €4.64m and the directors state that "these expenses continued to be tightly controlled and are driven primarily by payroll costs and amortisation". The business last year recorded the pre-tax losses after booking combined non-cash depreciation and amortisation costs of €684,404. The loss also takes into account a loss of €60,366 in exchange differences and restructuring costs of €32,869. The firm's lease costs increased from €334,854 to €408,847. The firm did benefit from an R&D tax credit of €58,937. Numbers employed decreased from 66 to 64 with 31 in editorial. 18 in technology and development, 12 in general and administration and three in sales and marketing. Staff costs - that included the bonus payment of €556,958 - last year totalled €5.8m that was an increase on the €5.69m paid out in the prior year. Former RTE Primetime presenter Mark Little set up the company in 2010 and Mr Little and the company's investors sold it to News Corp for €18m in December 2013. A note attached states that the directors have considered the losses to date and report that they are satisfied that appropriate measures have been taken to bring about the company's profitability. The note states that funding provided by and available from the shareholder is sufficient to enable the company to meet its liabilities as they fall due. The pay package for directors increased from €868,656 to €925,928, which was made up of remuneration of €731,907, €160,071 under long term incentive plans and €33,950 in pension contributions. At the end of June last, accumulated losses of €58.52m were offset by the share premium account of €59m and called up share capital of €392,075 - resulting in shareholders' funds of €908,278.
